Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1024 - 1032
Section I - De la conception à la production
DOI https://doi.org/10.1051/medsci/200925121024
Publié en ligne 15 décembre 2009
  1. Schneider CK. Monoclonal antibodies: regulatory challenges. Current Pharmaceutical Biotechnology 2008; 9 :431–8.
  2. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression system: an overview of the current upstream technologies. Curr Pharm Biotechnol 2008; 9 : 447–67.
  3. Seamans TC, Fries S, Beck A, et al. Cell cultivation process transfer and scale up in support of the production of early clinical supplies of an anti-IGF-1R antibody (part I). BioProcess Int 2008; 3 : 26.
  4. Beck A, Klinguer-Hamour C, Bussat MC, et al. Peptides as tools and drugs for immunotherapies. J Pept Sci 2007; 13 : 588–602.
  5. Beck A, Wagner-Rousset E, Goetsch L, et al. Therapeutic antibodies: structure assessment by mass spectrometry from screening to clinical batches. Screening Trends Drug Discov 2008; 9 : 18–20.
  6. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30.
  7. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins. Curr Pharm Biotechnol 2008; 9 : 482–501.
  8. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7.
  9. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81 : 6851–5.
  10. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321 : 522–5.
  11. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348 : 552–4.
  12. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368 : 856–9.
  13. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7 : 13–21.
  14. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, et al. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3 : 1157–71.
  15. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20 : 450–9.
  16. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20 : 436–3.
  17. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7 : 1401–13.
  18. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25 : 1369–72.
  19. Van der Neut Kolfschoten M., Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317 : 1554–7.
  20. Dillon TM, Ricci MS, Vezina C, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283 : 16206–15.
  21. Yoo EM, Wims LA, Chan LA, et al. Human IgG2 can form covalent dimers. J Immunol 2003; 170 : 3134–8.
  22. Liu YD, Chen X, Enk JZ, et al. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008; 283 : 29266–72.
  23. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20 : 460–70.
  24. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25 : 1256–64.
  25. Natsume A, In M, Takamura H, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68 : 3863–72.
  26. Angal S, King DJ, Bodmer MW, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30 : 105–8.
  27. Kai M, Motoki K, Yoshida H, et al. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nat Biotechnol 2008; 26 : 209–11.
  28. Wurch T, Lowe P, Caussanel V, et al. Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation. Curr Pharm Biotechnol 2008; 9 : 502–9.
  29. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358 : 1109–17.
  30. Wagner-Rousset E, Bednarczyk A, Bussat MC, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872 : 23–37.
  31. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6 : 1161–73.
  32. Hamilton SR, Gerngross TU. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007; 18 : 387–92.
  33. Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320 : 373–6.
  34. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20 : 471–8.
  35. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20 : 479–85.
  36. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008; 7 : 641–2.
  37. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26 : 985–90.
  38. Moon JY, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008; 49 : 389–99.
  39. Beck A, Bussat MC, Zorn N, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819 : 203–18.
  40. Vlasak J, Ionescu R. Heterogeneity of Monoclonal Antibodies relvealed by charge-sensitive methods. Curr Pharm Biotechnol 2008; 9 : 468–81.
  41. Beck A, Wurch T, Corvaïa N. Editorial: therapeutic antibodies and derivatives: from the bench to the clinic. Curr Pharm Biotechnol 2008; 9 : 421–2.
  42. Swann PG, Tolnay M, Muthukkumar S, et al. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008; 20 : 493–9.
  43. Kim MS, Lee SH, Song MY, et al. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 2007; 374 : 1374–88.
  44. Aggarwal S. What’s fueling the biotech engine-2007. Nat Biotechnol 2008; 26 : 1227–33.
  45. Gires O. EpCAM, une protéine versatile impliquée dans l’oncogenèse. Med Sci (Paris) 2009; 25 : 449–50.
  46. Faye L, Champey Y. Plantes, médicaments et génétique : quelles applications pour demain ? Med Sci (Paris) 2008; 24 : 939–45.
  47. Beck A, Iver H, Reichert JM. European Medecines Agency workshop on biosimilar monoclonal antibodies Meeting Report (London, UK, July 2, 2009). mAbs-Landes Bioscience 2009; 5 : 394–416. (http://www.landesbioscience.com/journals/mabs/article/9630).
  48. Beck A, Cochet O, Wurch T. GlycoFi’s technology to control the glycosylation of recombinant therapeutic proteins. Expert Op Drug Discov 2010 (sous presse).

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.